prophetic article, page-34

B
oh and these
>>I know nothing about off-label use in the area of HIV, so I won't comment on that.
if ATC were approved in later-line/salvage, i imagine you could expect off label use to be a significant component of revenue...

>>Pricing isn't likely to be huge
as above i think there is some pretty clear guidance here, yeah, only $5-6k per patient per year with a lazy 100-150k pts... do the sums...

just need to clarify the path to market and some cash to get there...

but lets not get ahead of ourselves...

Something we all agree on...
I havent heard anyone support the old drongo...

DRONA MUST GO

VOTE NOW FOR ALL RESOLUTIONS